StockNews.AI
JNJ
StockNews.AI
140 days

Johnson & Johnson Announces Expected Closing Date for Intra-Cellular Acquisition

1. JNJ's acquisition of Intra-Cellular Therapies is confirmed for April 2025. 2. Expected sales growth boost by 0.8%, adding $0.7 billion revenue.

M&A
+1.38%Current Return
VS
+0.61%S&P 500
$153.2504/01 04:20 PM EDTEvent Start
$155.3604/02 10:57 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

The acquisition is expected to enhance JNJ's revenue, similar to past successful acquisitions like Actelion that boosted sales and stock value significantly.

How important is it?

This news directly relates to future growth potential for JNJ, impacting investor sentiment and strategic positioning.

Why Long Term?

While immediate sales growth is projected, the full integration benefits may take longer to materialize, impacting JNJ’s growth trajectory persisting into subsequent years.

Related Companies

ITCI
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that following the approval of its pending acquisition of Intra-Cellular Therapies, Inc. by Intra-Cellular Therapies' shareholders on March 27, 2025, Johnson & Johnson intends to complete its acquisition of Intra-Cellular Therapies on or around April 2, 2025. The transaction is expected to accelerate 2025 sales growth for Johnson & Johnson by approximately 0.8% with approximately $0.7 billion in incr.

Related News